Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Pulmonary Arterial Hypertension

• Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
• A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
• Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
• 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
• Study of Intravenous ZMA001 in Healthy Subjects
• The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
• Anti-CD20 Antibodies for Treatment of SLE-PAH
• Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
• Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
• A Study of Macitentan in Children Below 2 Years of Age
• Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
• A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
• A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
• Consistency of Electrical Cardiometry and Pulmonary Artery Catheter
• Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
• A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
• Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
• Empagliflozin in Pulmonary Arterial Hypertension
• PET Image in PAH Patients
• Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
• Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
• A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
• Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
• Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
• a Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients With Renal Insufficiency and Healthy Subjects
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
• Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
• Dapagliflozin in Pulmonary Arterial Hypertension
• A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
• Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
• A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
• Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
• Xenon MRI Pulm Hypertension
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
• Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
• Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
• Effect of Food on BIA 5-1058
• Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
• Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
• Apabetalone for Pulmonary Arterial Hypertension
• Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
• A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality
• Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study
• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
• Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients
• Single-Dose, Open Label Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
• Pulmonary Hypertension SOLAR
• A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)
• Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
• Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR)
• Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
• A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers
• A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
• Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension
• GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
• Positioning Imatinib for Pulmonary Arterial Hypertension
• Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH
• TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
• The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
• Oral CXA-10 in Pulmonary Arterial Hypertension
• A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
• Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
• Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
• CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
• Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
• Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
• Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
• Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
• A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
• Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
• Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
• Upfront Combination Pulmonary Arterial Hypertension Therapy
• Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
• Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
• Olaparib for PAH: a Multicenter Clinical Trial
• This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thro
• A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
• Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
• Effects of DHEA in Pulmonary Hypertension
• Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
• Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
• Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
• Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
• Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
• Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
• Subcutaneous Elafin in Healthy Subjects
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
• Effect of BIA 5 1058 on Cardiac Repolarization
• Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
• PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
• Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
• Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension
• (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
• Spironolactone Therapy in Chronic Stable Right HF Trial
• A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
• The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
• Olaparib for PAH: a Pilot Study
• Goal Oriented Strategy to Preserve Ejection Fraction Trial
• Pulmonary Hypertension and Anastrozole Trial
• Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
• A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
• Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
• Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
• Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
• : Vascular Function in Health and Disease
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
• Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
• [18F]FES PET/CT in PAH
• Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
• Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
• Crossover Study From Macitentan or Bosentan Over to Ambrisentan
• An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
• Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
• Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
• Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
• Acute Effects of Benzbromaron on the Pulmonary Circulation
• Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension
• A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
• Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
• Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
• Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
• A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
• Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
• A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
• Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
• ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension
• Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
• Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
• Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
• A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
• Beta-blockers in Pulmonary Arterial Hypertension
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
• Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide
• Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
• Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
• Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
• A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
• Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
• Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
• The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
• Selonsertib in Adults With Pulmonary Arterial Hypertension
• Safety of Terbogrel in Patients With Primary Pulmonary Hypertension
• Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
• Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
• Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
• OPsumit USers Registry
• Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
• Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
• Trimetazidine in Pulmonary Artery Hypertension
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
• Effects of Oral Sildenafil on Mortality in Adults With PAH
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
• Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
• Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
• Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
• Hydroxyurea in Pulmonary Arterial Hypertension
• Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
• A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
• Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
• Beraprost-314d Added-on to Tyvaso® (BEAT)
• Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
• Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
• (-)-Epicatechin and Pulmonary Arterial Hypertension
• To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
• Iron Status and Hypoxic Pulmonary Vascular Responses
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
• Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
• A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
• Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
• A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
• Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
• Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
• A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
• Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
• Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
• Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
• A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
• Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
• Bosentan and Pulmonary Endothelial Function
• Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
• Spironolactone for Pulmonary Arterial Hypertension
• Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
• Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
• FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
• Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
• Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
• Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
• Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
• The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
• Remodulin® to Oral Treprostinil Transition
• PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
• An Open Label Access Study For Subjects Who Completed A1481156
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
• Inhaled Treprostinil for PAH: Open-label Extension
• Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
• Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
• Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
• Anastrozole in Patients With Pulmonary Arterial Hypertension
• Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
• Revatio Portal-Pulmonary Arterial Hypertension Trial
• A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
• Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
• Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
• Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
• A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
• Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
• Effects of Apelin on the Lung Circulation in Pulmonary Hypertension
• IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
• Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
• Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
• Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension
• Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
• Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
• Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
• Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
• Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
• Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
• Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
• Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
• Efficacy of Ventavis Used in Real-life Setting.
• Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)
• Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
• An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
• FUTURE 3 Study Extension
• Efficacy and Safety of Ambrisentan in Children 8-18yrs
• Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
• Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
• Treprostinil Combined With Tadalafil for Pulmonary Hypertension
• Iron Deficiency In Pulmonary Hypertension
• Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
• Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
• The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
• Drug Interaction Between Ritonavir And Sitaxsentan
• Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
• Beta-blockers in i-PAH
• A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
• Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
• Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
• A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
• Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
• A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
• Ranolazine and Pulmonary Hypertension
• A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
• Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
• Nitric Oxide, GeNO Nitrosyl Delivery System
• Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
• The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
• ACT-293987 in Pulmonary Arterial Hypertension
• Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
• Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
• Epoprostenol for Injection in Pulmonary Arterial Hypertension
• Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)
• Tezosentan in Patients With Pulmonary Arterial Hypertension
• Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
• Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
• Tezosentan in Pulmonary Arterial Hypertension
• Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
• Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
• Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
• A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
• A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
• A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin
• Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
• Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
• Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
• Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
• Effect of Food on the Pharmacokinetics of Oral Treprostinil
• To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
• Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
• Early Therapy of Pulmonary Arterial Hypertension
• Ventavis® Registry Protocol
• Imatinib (QTI571) in Pulmonary Arterial Hypertension
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
• Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
• Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
• Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
• A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
• BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
• A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
• Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
• Insulin Resistance in Pulmonary Arterial Hypertension
• Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
• Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
• A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
• A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
• Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
• Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
• Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
• An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
• A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
• Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
• FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
• The Assessment of Right Ventricular Contractility in Response to Sildenafil
• Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
• Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
• The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension
• Iloprost Power 15 in Pulmonary Arterial Hypertension
• Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
• Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
• A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
• Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
• Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
• Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
• Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
• Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
• Pharmacogenomics in Pulmonary Arterial Hypertension
• Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
• Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
• A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
• A Study to Evaluate GSK1325760A - a Long-Term Extension Study
• Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
• Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
• Hemodynamic Response After Six Months of Sildenafil
• Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
• Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension
• Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
• Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
• Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
• 6R-BH4 Pulmonary Arterial Hypertension Study
• Combination Therapy in Pulmonary Arterial Hypertension
• To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
• Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
• Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
• A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
• BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
• Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
• Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
• Bosentan in Children With Pulmonary Arterial Hypertension
• Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
• Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
• Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
• The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
• Bosentan in Treatment of Pulmonary Arterial Hypertension
• Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia
• Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
• Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
• A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
• Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
• A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
• Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
• PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
• Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
• A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
• Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
• ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
• Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
• Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
• Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
• Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension